Anti-amyloid immunotherapies represent the first disease-modifying treatments for Alzheimer's disease, targeting the accumulation of amyloid-beta (Aβ) plaques in the brain. This comparison matrix provides a comprehensive analysis of the major monoclonal antibody therapies that have reached late-stage clinical development, examining their mechanisms of action, clinical trial results, safety profiles, and practical considerations for clinical use.
All FDA-approved anti-amyloid immunotherapies are monoclonal antibodies administered intravenously. They differ in their specific targets:
| Therapy | Target | Type | Epitope |
|---|---|---|---|
| Lecanemab | Aβ protofibrils | IgG1 | Aβ1-16 |
| Donanemab | N-terminal truncated Aβ | IgG1 | Aβ3-7 |
| Aducanumab | Conformational epitopes | IgG1 | Aβ conformational |
| Gantenerumab | Aggregated Aβ | IgG1 | Aβ1-11/Aβ3-11 |
| Crenezumab | Oligomers and plaques | IgG4 | Aβ1-16 |
The different targets reflect distinct hypotheses about the most toxic form of Aβ:
Protofibrils are soluble, highly toxic Aβ aggregates that are believed to be the most pathogenic species. Lecanemab's focus on protofibrils may explain its favorable efficacy profile[1].
| Therapy | FDA Status | Year Approved |
|---|---|---|
| Lecanemab | Full approval | 2023 |
| Donanemab | Full approval | 2024 |
| Aducanumab | Withdrawn | N/A |
| Gantenerumab | Not approved | N/A |
| Crenezumab | Not approved | N/A |
Amyloid-related imaging abnormalities (ARIA) are the major safety concern with anti-amyloid immunotherapies:
| Therapy | ARIA-E Rate (Treatment) | ARIA-E Rate (Placebo) |
|---|---|---|
| Lecanemab | 12.6% | 1.7% |
| Donanemab | 24.0% | 1.0% |
| Aducanumab | 35.5% | 2.7% |
| Gantenerumab | 25.0% | 3.0% |
| Crenezumab | 6.5% | 4.5% |
| Therapy | ARIA-H Rate (Treatment) | ARIA-H Rate (Placebo) |
|---|---|---|
| Lecanemab | 17.3% | 9.0% |
| Donanemab | 31.4% | 13.6% |
| Aducanumab | 19.1% | 7.6% |
| Endpoint | Description | Meaningful Change |
|---|---|---|
| CDR-SB | Clinical Dementia Rating Sum of Boxes | 0.5-1.0 points |
| iADRS | Integrated Alzheimer's Disease Rating Scale | 3-4 points |
| ADAS-Cog | Alzheimer's Disease Assessment Scale-Cognitive | 3-4 points |
| MMSE | Mini-Mental State Examination | 2-3 points |
| Biomarker | What It Measures | Change Threshold |
|---|---|---|
| Amyloid PET (SUVr) | Amyloid plaque burden | >20 centiloid reduction |
| CSF p-tau181 | Tau pathology | Decrease indicates benefit |
| FDG-PET | Brain glucose metabolism | Reduced decline |
| Feature | Lecanemab | Donanemab | Aducanumab |
|---|---|---|---|
| Target | Protofibrils | N-truncated Aβ | Conformational |
| Dosing | 10 mg/kg q2w | 350-1400 mg q4w | 10 mg/kg q4w |
| Trial | CLARITY-AD | TRAILBLAZER-ALZ 2 | EMERGE |
| CDR-SB benefit | -0.45 | -4.2* | -0.22 |
| ARIA-E rate | 12.6% | 24.0% | 35.5% |
| FDA status | Approved | Approved | Withdrawn |
| Plaque removal | 59 centiloids | 52% complete | Significant |
*iADRS endpoint
Anti-amyloid immunotherapies represent a paradigm shift in Alzheimer's disease treatment. Lecanemab and Donanemab have demonstrated clinically meaningful benefits in early AD, though both require careful patient selection and monitoring for ARIA. The field continues to evolve with combination approaches and next-generation therapies in development.
van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in Early Alzheimer's Disease. N Engl J Med. 2023;388(1):9-21. 2023. ↩︎